We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Share this :
Print
Genscript SARS-CoV-2 ADE-Causing Antibody (S9HC)
Genscript SARS-CoV-2 ADE-Causing Antibody (S9HC) - GSCRPT (Additional S&H or Hazmat Fees May Apply)
List Price
$375.00
Your Price
$375.00
HOW MUCH YOU SAVE:
0.00 %
| NETA PART: | GSCRPT-A02133-100 |
| MFG.PART: | A02133-100 |
| UNSPSC: | 12352202 |
| Manufacturer: | GenScript USA Inc |
Overview
| Specificity | GenScript SARS-CoV-2 ADE-Causing Antibody (S9HC) reacts with SARS-CoV-2 Spike protein of wild type and delta variant. It can obviously enhance the SARS-COV-2 binding with ACE2. |
| Host Species | Humanized |
| Immunogen | SARS-CoV-2 Spike protein |
| Species Reactivity | Not applicable |
| Conjugate | Unconjugated |
Applications
| Working concentrations for specific applications should be determined by the investigator. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||
| |||||
Properties
| Form | Liquid |
| Storage Buffer | PBS, pH 7.2, Azide free |
| Concentration | 1 mg/ml |
| Endotoxin Level | < 10 EU/mg |
| Storage Instructions | Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. Avoid repeated freezing and thawing cycles. |
| Purification | Affinity chromatography |
| Isotype | Recombinant human IgG1 |
| Clonality | Monoclonal |
| Clone ID | S9HC |
Background
| Target Background | SARS-CoV-2 ADE-causing antibody is a SARS-CoV-2 Spike protein antibody that can exacerbate the COVID-19 disease severity of patients. Antibody-dependent enhancement (ADE) may be involved in the clinical observation of patients with increased severity of symptoms and high levels of SARS-CoV-2 antibodies. It is reported [1] that the same antibodies against the NTD domain of the SARS-CoV-2 spike protein have an ADE effect by increasing the binding of ACE2 to the spike protein. |
| Synonyms | Anti-SARS-CoV-2 ADE-Causing Antibody; SARS-CoV-2 Antibody-dependent enhancement Antibody; SARS-CoV-2 ADE response Antibody; SARS-CoV-2 Spike Antibody; SARS-CoV-2 ADE effect. |
| Reference | [1] Liu Y, Soh W T, Kishikawa J I, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. 2021. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
| SKU | GSCRPT-A02133-100 |
|---|---|
| Supplier Part Number | A02133-100 |
| UM | UN |
| UNSPSC | 12352202 |
| Manufacturer | GenScript USA Inc |
| ProductLine | GSCRPT |
| Qty | 1 |
| MinOrderQty | 1 |
| Weight | 7.00 |
| Lead Time | 7 Business Days |
| Hazardous | N |